Finance Foggle

FDA Approves Breakthrough Eye Drops That Fix Near Vision Without Glasses Key Takeaways Aspect Details Latest FDA Approval VIZZ eye drops approved July 2025, works up to 10 hours Active Ingredient Aceclidine 1.44% - first of its kind in the US How Long It Works Up to 10 hours per dose with once-daily application Effectiveness 71% of users gained 3+ lines of near vision improvement Availability Expected launch between October-December 2025 Other Options Vuity (pilocarpine) and QLOSI also FDA-approved Who Can Use It Adults with presbyopia (age-related near vision loss) Cost Coverage Insurance coverage varies, prescription required What Are These Revolutionary Eye Drops? The FDA just approved VIZZ, the first and only aceclidine-based eye drop for treating presbyopia, marking a global first in this treatment category. This isn't your grandfather's reading glasses solution - we're talking about drops that can give you clear near vision for up to 10 hours with just one d...

  Key Takeaways Sarepta Therapeutics stock plunged ~40% following a second patient death linked to its gene therapy Elevidys . FDA may pull Elevidys off the market as safety concerns mount; shipments halted for non-ambulatory patients . Therapy initially approved controversially in 2023 for ages 4-5, later expanded amid efficacy debates . Year-to-date stock loss exceeds 87%, erasing billions in market value . Duchenne muscular dystrophy patients face renewed uncertainty as treatment risks outweigh benefits for some . The Bloodbath on Nasdaq Sarepta Therapeutics stock cratered 40% in premarket trading June 16, 2025. It opened at $13.60, a far cry from its 52-week high of $150.48 . The collapse wasn't a surprise to those watching the ticker. Shares had been dying a slow death all year. By July, the year-to-date loss hit 87.5% . Shareholders stared at ruins. Trading volume exploded to 60 million shares. Average volume is 5.9 million . The market cap vaporized, $1.336 billion intraday....